CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2023; 7: (11) ; 16-19 ; DOI: 10.12208/j.ijcr.20230343.

Research progress of exosomes in lung cancer
外泌体在肺癌中的研究进展

作者: 阿地来古丽·肉孜 *, 安静

新疆医科大学第二附属医院 新疆乌鲁木齐

*通讯作者: 阿地来古丽·肉孜,单位:新疆医科大学第二附属医院 新疆乌鲁木齐;

发布时间: 2023-11-21 总浏览量: 291

摘要

外泌体是一种由细胞分泌的纳米级胞外囊泡。有研究表明,外泌体在疾病治疗和药物递送系统中有较高的研究价值和临床应用前景。外泌体对多种免疫细胞进行免疫调控,改变了肿瘤微环境,同时还可以促进肿瘤血管的新生,通过这些方式影响了肿瘤进展。本文对已有研究资料进行了整理,并归纳出外泌体在肺癌增殖及诊治中所起的作用,从而为临床治疗肺癌提供理论上的参考。

关键词: 外泌体;肺癌;转移;治疗

Abstract

Exosomes are nanoscale extracellular vesicles secreted by cells. Some studies have shown that exosomes have high research value and clinical application prospects in disease treatment and drug delivery systems. Exosomes regulate a variety of immune cells, change the tumor microenvironment, and can also promote tumor angiogenesis, which affects tumor progression through these ways. In this paper, the existing research data were summarized and the role of exosomes in the proliferation, diagnosis and treatment of lung cancer was summarized, so as to provide theoretical reference for clinical treatment of lung cancer.

Key words: Exosome; Lung cancer; Transfer; Heal

参考文献 References

[1] Alipoor SD,Mortaz E,Varahram M,et al.The potential biomark-ers and immunological effects of tumor-derived exosomes in lung cancer[J].Front Immunol, 2018,9:819.

[2] Li K,Chen Y,Li A,et al. Exosomes play roles in sequential processes of tumor metastasis[J].Int J Cancer, 2019,144(7): 1486-1495.

[3] Pullan JE, Confeld MI, Osborn JK, et al. Exosomes as drug carriers for cancer therapy[J]. Mol Pharm, 2019,6(5):1789-1798.

[4] Wang J, Zhao X, Wang Y,et al. circRNA-002178 act as a ceR-NA to promote PDL1/PD1 expression in lung adenocarcinoma[J]. Cell Death Dis, 2020,11(1):32.

[5] Wang J,Sun X,Zhao J,et al. Exosomes: A novel strategy for treatment and prevention of diseases[J]. Front Pharmacol, 2017, 8:300.

[6] Seo N,Akiyoshi K,Shiku H.Exosome-mediated regulation of tumor immunology[J].Cancer Sci, 2018, 109(10): 2998-3004. 

[7] Yi M,Xu L,Jiao Y,et al.The role of cancer-derived microR-NAs in cancer immune escape[J].J Hematol Oncol,2020, 13(1):25.

[8] 曾娟,马士淇,张璐,张雨阳,朱桂全,曹邦荣.外泌体在肺癌免疫治疗中的作用[J].肿瘤预防与治疗,2023,36(08):702-708.

[9] Liang X, Zhang L, Wang S, Han Q,Zhao RC. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a.J Cell Sci.2016; 129(11):2182-9.

[10] Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. J Cell Physiol.  2018; 233(9):6370-80. 

[11] Alipoor SD, Mortaz E, Garssen J, Movassaghi M, Mirsaeidi M, Adcock IM. Exosomes and Exosomal miRNA in Respiratory  Diseases. Mediators Inflamm. 2016;2016: 5628404.

[12] 吴小凤,詹日明,程大钊,陈黎,王天雨,唐旭东.非小细胞肺癌细胞外泌体源性FZD10促进体外血管生成[J].南方医科大学学报,2022,42(09):1351-1358.

[13] 血浆外泌体miRNAs在肺癌诊断中的价值及外泌体miR-1246对血管功能影响的研究.张倩.中国人民解放军空军军医大学,2022

[14] 路通,邹志田,裴艳志,乔峰,朱晓峰.非小细胞肺癌患者血清外泌体中表皮生长因子受体的表达情况及其对NCI-H1299细胞增殖和侵袭的影响[J].广西医学,2020,42(07): 835-840.

[15] 余圆圆.益气解毒方及其组分血根碱通过调控肺癌细胞源外泌体抑制巨噬细胞促进肺癌增殖转移作用的机制研究[D].上海中医药大学,2020.000501.

[16] KIM D H,PARK S, KIM H,et al. Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metasis throught the inhibition of RCAV1.4[J]. Cancer Lett, 2020, 475: 2-13.

[17] NIE H,NIE X, ZHANG D, et al. Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer[J].Nanoscale, 2020,12(2):877-87.

[18] HU C, MEINERSNSN, LUKAS C, et al.Role of exsomoal microENAs inlung cancer biology and cilinical appilications [J]. Cell Prilif, 2020, 53(6):el2828.

[19] MARKOPOULOS G S, ROUPAKIA E, TOKAMANI M,et al. A step-by-step microRNA guide to cancer development and metastasis[J].Cell Oncol(Dordr),2017,40(4):303-39.

[20] LIX, CHEN Y, WANG J,et al.Lung Cancer Cell-Derived Exosomal Let-7d-5p Down-Regulates OPRM1 to Promote Cancer-Induced Bone Pain[J]. Front Cell Dev Biol,2021, 9:666857. 

[21] ZHANG J, WU J.The Potential Roles of Exosomal miR-214 in Bone Metastasis of Lung Adenocarcinoma[J]. Front Oncol, 2020, 10:611054.

[22] KUBO H.Extracellular Vesicles in Lung Disease[J].Chest, 2018, 153(1):210-6.

[23] 纪敬斌,张宸瑜,彭垒,等.非小细胞肺癌新辅助免疫治疗的研究进展、获益人群、治疗周期和疗效预测[J].中国肺癌杂志,2022,25(2):92-101.

[24] Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory[J].Cell, 2019,177(2):414-427.

[25] Zhou J, Mahoney KM, Giobbie-Hurder A, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade[J].Cancer Immunol Res, 2017, 5(6): 480-492.

[26] Okuma Y, Wakui H, Utsumi H,et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non_small-cell lung cancer[J].Clin Lung Cancer, 2018, 19(5): 410- 417.

[27] Costantini A, Julie C, Dumenil C,et al. Predictive role of plas-matic biomarkers in advanced non-small cell lung cancer treated by nivolumab[J]. Oncoimmunology, 2018, 7(8): e1452581.

[28] Nicolazzo C,Raimondi C,Mancini M,et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer pa tients treated with the PD-1 inhibitor Nivolumab [J]. Sci Rep,2016,6: 31726.

[29] Yang Q, Chen M, Gu J,et al. Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients[J].Front Immunol, 2021,12:665133.

[30] Del Re M, Marconcini R, Pasquini G,et al. PD-L1 mRNA ex-pression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC[J].Br J Cancer, 2018,118(6):820-824.

[31] 舒春露,朱大兴,周清华.非小细胞肺癌新辅助免疫治疗生物标志物研究进展[J].中国肺癌杂志.2022,25(2):130-136.

[32] 舒春露,朱大兴,周清华.非小细胞肺癌新辅助免疫治疗生物标志物研究进展[J].中国肺癌杂志.2022,25(2):130-136.

[33] 李牧洋,王婷婷,陈波,等.电针足三里-环跳穴对不同状态大鼠血清外泌体表达的影响[J]. 陕西中医,2019,40(2): 139-142.

[34] 李晶晶,季青,刘煊,等.滋阴化痰方调控肿瘤细胞来源外泌体对HUVECs管样分化的影响[J] 中医学报,2021, 36(1): 118-125.

引用本文

阿地来古丽·肉孜, 安静, 外泌体在肺癌中的研究进展[J]. 国际临床研究杂志, 2023; 7: (11) : 16-19.